Eli Lilly and Company (NYSE:LLY<\/b>) is among the stocks in focus, as Jim Cramer analyzed the broader market impact of the recent AI data center rally<\/b>. Cramer highlighted the FDA approval of the company\u2019s new weight loss pill and its acquisition of Centessa Pharmaceuticals, as he stated:<\/p>\n Today, we got big news from Eli Lilly. The Indianapolis colossus got approval for Foundayo, which is now the only GLP-1 weight loss pill that can be taken any time of day without food or water restrictions. It\u2019s almost as strong as the injections. Starts at $25 per month of commercial coverage or between $149 and $349 per month if you\u2019re paying out of pocket. When placed head-to-head against the competing pill from Novo Nordisk, I think Lilly\u2019s got a winner\u2026 Ironically, though, the biggest news from Lilly may have been something that happened yesterday. That\u2019s the acquisition of Centessa Pharmaceuticals, a biotech company, for $7.8 billion.<\/p>\n Centessa is trying to combat narcolepsy and other neurological disorders. They\u2019re working on a neuropeptide called orexin, which is apparently something that people with narcolepsy are missing or don\u2019t have a lot of. It\u2019s possible that orexin can be used for much more than narcopsy\u2026 I like what Lilly\u2019s doing here. It\u2019s tackling some of the hardest to treat illnesses, ones that have often baffled and befuddled those drug companies that have attempted to beat mental illness. The path towards successful neurological treatment is littered with failures. The money that Lilly gets from its weight loss drug is being used wisely to come up with breakthrough drugs\u2026 Most importantly, though, let\u2019s own the stock because I think this weight loss pill will be a blockbuster. And that\u2019s why we\u2019ve stuck with Eli Lilly for the Charitable Trust.<\/p>\n<\/blockquote>\n Stock market data. Photo by Burak The Weekender on Pexels<\/p>\n Eli Lilly and Company (NYSE:LLY) develops and markets medicines for diabetes, obesity, oncology, immunology, neuroscience, and other chronic conditions.<\/p>\n While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/b>.<\/p>\n READ NEXT: <\/b>33 Stocks That Should Double in 3 Years<\/b> and <\/b>15 Stocks That Will Make You Rich in 10 Years<\/b>\u00a0<\/b><\/p>\n Disclosure: None. Follow Insider Monkey on Google News<\/b>.<\/b><\/p>\n<\/p><\/div>\n\n
<\/div>\n<\/div>\n<\/figure>\n